Fig. 5

The role of Trim-Away pathway in Ab@Tf-Cou6-PLGA NPs-mediated BCR/ABL degradation. a Proteasome inhibitor MG132 (100 nM) treatment weakened the BCR/ABL degradation effects of Ab@Tf-Cou6-PLGA NPs in CML cells. b The suppression effect of Ab@Tf-Cou6-PLGA NPs on BCR/ABL was reduced by TRIM21 knockdown. c Immunofluorescence assay was used to analyze the colocalization of BCR/ABL and TRIM21 after Ab@Tf-PLGA NPs treatment. Scale bar, 10 μm. d Co-IP analysis of the interaction of BCR/ABL and TRIM21 with Ab@Tf-Cou6-PLGA NPs treatment. e Co-IP analysis of the interaction of BCR/ABL and TRIM21 without Ab@Tf-Cou6-PLGA NPs treatment